<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05064839</url>
  </required_header>
  <id_info>
    <org_study_id>2021-A00732-39</org_study_id>
    <nct_id>NCT05064839</nct_id>
  </id_info>
  <brief_title>Imaging for the Evaluation of Transthyretin Cardiac Amyloidosis Prevalence of Patients Over 65 Hospitalized in Cardiology Wards (the IMPACT Study)</brief_title>
  <acronym>IMPACT</acronym>
  <official_title>Imaging for the Evaluation of Transthyretin Cardiac Amyloidosis Prevalence of Patients Over 65 Hospitalized in Cardiology Wards (the IMPACT Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure with preserved ejection and hypertrophic cardiomyopathy are common diseases and&#xD;
      often associated with transthyretin cardiac amyloidosis (TTR-CM), especially in elderly&#xD;
      people. Nevertheless, research of TTR-CM is recommended in patients with ventricular&#xD;
      hypertrophy without other cause such as valvular disease or hypertension. Therefore, the&#xD;
      exact prevalence of TTR-CM remains unknown. We aim to determine the prevalence of TTR-CM in&#xD;
      patients with ventricular hypertrophy and aged ≥ 60 years old, hospitalized in our cardiology&#xD;
      department (CHU de Poitiers) by performing bone scintigraphy and research of AL amyloidosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Not Provided&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 6, 2021</start_date>
  <completion_date type="Anticipated">October 6, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 6, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with a positive bone scintigraphy (perugini score&gt; or = 2) in the absence of AL cardiac amyloidosis.</measure>
    <time_frame>At Visit 2, one to four months after inclusion visit.</time_frame>
    <description>Percentage of patients with a positive bone scintigraphy (perugini score&gt; or = 2) in the absence of AL cardiac amyloidosis in patients over 60 years hospitalised in cardiology wards, with an hypertrophy of the left ventricle on transthoracic echocardiography (thickness of the left ventricle at the end of diastole &gt;12mm), whatever the possible cause of hypertrophy of the left ventricle (other potential cause not excluded), and without prior diagnosis of cardiac amylosis.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Transthyretin Cardiac Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Bony scintigraphy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bony scintigraphy within 1 to 4 months after inclusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bony scintigraphy</intervention_name>
    <description>Bony scintigraphy (99mTc-Hydromethylene diphosphonate) will be performed in all patients with hypertrophy of the left ventricle</description>
    <arm_group_label>Bony scintigraphy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient ≥ 60 years, hospitalised in cardiology wards of the Centre Hospitalier&#xD;
             Universitaire of Poitiers&#xD;
&#xD;
          -  Left ventricle hypertrophy on echocardiography&#xD;
&#xD;
          -  Patient able to comply with study procedures&#xD;
&#xD;
          -  Patient legally free and not subject to any custody, guardianship, tutelage or&#xD;
             subordination measures&#xD;
&#xD;
          -  Patient having signed an informed consent after clear and fair information on the&#xD;
             study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CardiacTransplant&#xD;
&#xD;
          -  Complex congenital cardiopathies&#xD;
&#xD;
          -  Know diagnosis of amylosis&#xD;
&#xD;
          -  Contra-indication to bony scintigraphy : hypersensitivity to sodium oxidronate or one&#xD;
             of its excipients, or to one of the components of radiopharmaceutic marked product ;&#xD;
&#xD;
          -  Subject not able to comply with study procedures&#xD;
&#xD;
          -  Patients not benefiting from a Social Security scheme or not benefiting from it&#xD;
             through a third party&#xD;
&#xD;
          -  Persons benefiting from enhanced protection, namely minors, persons deprived of their&#xD;
             liberty by a judicial or administrative decision, patients staying in a health or&#xD;
             social establishment, adults under legal protection, and patients in emergency&#xD;
             situation.&#xD;
&#xD;
          -  Women not menopausal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Claire BOULETI, MD</last_name>
    <phone>+33 5 49 44 43 25</phone>
    <email>claire.bouleti@chu-poitiers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>C.H.U. de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ALOS Benjamin, MD</last_name>
      <phone>+33549441984</phone>
      <email>benjamin.alos@chu-poitiers.fr</email>
    </contact>
    <contact_backup>
      <last_name>FOUASSIER David, MD</last_name>
      <phone>+33549442922</phone>
      <email>david.fouassier@chu-poitiers.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 26, 2021</study_first_submitted>
  <study_first_submitted_qc>September 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

